ClinicalTrials.gg

Program

THB335

A development code. Also written as “THB335 Lower Dose”, “THB335 Higher Dose” and “THB335 single dose”.

Its studies are mostly in Chronic Urticaria, led by 2 companies.

Furthest: phase 2, since Aug 11, 20262 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Calixis11 open or runningphase 2since Aug 11, 2026Aug 11, 2026Dec 31, 2027phase 2 · NCT07766499
Third Harmonic Bio10 open or runningphase 1since May 15, 2024May 15, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2024First study: phase 1 study in HealthyNew to Third Harmonic BioThird Harmonic Bio · NCT06425861 · 60 enrolled · United States
  2. Aug 11, 2026Calixis's first study: phase 2 study in Chronic UrticariaNew to CalixisCalixis · NCT07766499 · 81 planned · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaCalixis · NCT07766499

TargetBeta

KIT →read by rule
“THB335 is a highly potent and selective inhibitor of the receptor tyrosine kinase KIT that is expressed on mast cells.”study text, by rule · the study

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
velzatinibGlaxoSmithKlinephase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
elenestinibSanofiphase 33
NB-003ruleningbo-newbay-technology-development-co-ltdphase 32
briquilimabrulejasper-therapeutics-incphase 27

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07766499Chronic Urticaria · United States2RecruitingCalixisDec 31, 202781
NCT06425861Healthy · United States1CompletedThird Harmonic BioDec 18, 202460

How it is read

Names in the registry

  • “THB335 Lower Dose”, 1 entry
  • “THB335 Higher Dose”, 1 entry
  • “THB335 single dose”, 1 entry
  • “THB335 fasted/fed”, 1 entry
  • “THB335 multiple dose”, 1 entry

Codes read as this program: THB335.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.